Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eszopiclone - Sunovion Pharmaceuticals

Drug Profile

Eszopiclone - Sunovion Pharmaceuticals

Alternative Names: Esopiclone; Estorra; Lunesta; Lunivia; S-Zopiclone; SEP-0227018; SEP-190; SEP-225441

Latest Information Update: 06 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Eisai Co Ltd; Sepracor; Sunovion Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Esters; Hypnosedatives; Piperazines; Pyrazines; Pyridines; Pyrroles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia
  • No development reported Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 30 Apr 2019 The FDA recommends to update the label of eszopiclone (Lunesta®) for Insomnia to include Black Box warning regarding the complex sleep behaviors
  • 31 May 2018 Eisai completes a phase II trial for Insomnia in Japan (PO) (UMIN000024462)
  • 01 Oct 2016 Eisai initiates enrolment in a phase II trial for Insomnia in Japan (PO) (UMIN000024462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top